DUBLIN--(BUSINESS WIRE)--The "Drug Delivery Infusion Systems - Medical Devices Pipeline Assessment, 2017" report has been added to Research and Markets' offering.
The Medical Devices sector report provides an overview of Drug Delivery Infusion Systems currently in pipeline stage.
The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Drug Delivery Infusion Systems pipeline products.
Scope of the Report:
- Extensive coverage of the Drug Delivery Infusion Systems under development.
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities.
- The report reviews the major players involved in the development of Drug Delivery Infusion Systems and list all their pipeline projects.
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved/Issued stage.
- The report provides key clinical trial data of ongoing trials specific to pipeline products.
- Recent developments in the segment/industry.
- BioCardia Inc
- BioQ Pharma Inc
- ClearLine MD
- Debiotech SA
- Edwards Lifesciences Corp
- Eksigent Technologies LLC
- Elcam Medical
- Eli Lilly and Co
- EryDel SPA
- Flowonix Medical Inc
- FluidSynchrony, LLC
- Fluonic, Inc.
- Fresenius Kidney Care
- Hospira Inc
Key Topics Covered:
1 Table of Contents
3 Products under Development
4 Drug Delivery Infusion Systems - Pipeline Products under Development by Companies
5 Drug Delivery Infusion Systems Companies and Product Overview
6 Drug Delivery Infusion Systems- Recent Developments
For more information about this report visit https://www.researchandmarkets.com/research/n7tmsz/drug_delivery